Sanofi announces the official commercialization and listing of Leweichu in China. Today, it was learned from Sanofi that the company's long-acting monoclonal antibody Leweichu (Nisevirumab Injection), a respiratory syncytial virus (RSV) prevention measure for all infants, has been officially commercialized and launched in China. The Caixin News Agency reporter learned that the new drug application for this product was approved by the National Medical Products Administration in December 2023, and is currently the first and only innovative method approved in China for the prevention of lower respiratory tract infections caused by the syncytial virus in infants.